Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids

Thorax

Volumn 59, Issue 9, 2004, Pages 761-768

  Campbell, I A ^a   Douglas, J G ^b   Francis, R M ^c   Prescott, R J ^d   Reid, D M ^e  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; ETIDRONIC ACID; GLUCOCORTICOID; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHMA; BONE DENSITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; FEMALE; FOLLOW UP; FRACTURE; HEADACHE; HUMAN; HYPERCALCEMIA; INDIGESTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SHOULDER PAIN; TIME; VOMITING;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ASTHMA; BONE DENSITY; CALCIUM; ETIDRONIC ACID; FEMALE; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; MALE; OSTEOPOROSIS;

EID: 4544316328     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2003.013839     Document Type: Article

References (44)

1. Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996;313:344-6.
2. Peat DI, Healy S, Reid DM, et al. Steroid-induced osteoporosis: no opportunity for prevention? Ann Rheum Dis 1995;54:66-8.
3. van Staa T, Leukens HGM, Abenheim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
4. Boland EW, Hedley NE. Management of rheumatoid arthritis with small doses of cortisone acetate. JAMA 150, 144:36-70.
5. Curtess PH, Clarke WS, Hernon CH. Vertebral fractures resulting from prolonged cortisone and corticotrophin therapy. JAMA 1954;156:467-9.
6. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenosis and management. Ann Intern Med 1990;112:352-64.
7. Adinoff AD, Hollister MD. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
8. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with post-menopausal osteoporosis. N Engl J Med 1990;322:1265-71.
9. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate in the treatment of post-menopausal osteoporosis. N Engl J Med 1990;323:73-9.
10. Reid IR, King AR, Alexande CJ, et al. Prevention of steroid-induced osteoporosis with 3-amino-hydroxypropylidene-1, 1,bisphosphonate (APD). Lancet 1988;1:143-6.
11. Reid IR, Heap SW, King AR, et al. Two year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988;2:1144-5.
12. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry:patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14.
13. Genant HK, Li J, Wu CY, et al. Vertebral fractures in osteoporosis: a new method for clinical assessment J Clin Densitom 2000;3:281-90.
14. Crooks SW, Colman SB, Campbell IA. Costs and getting ethical approval deter doctors from participating in multi-centre trials. BMJ 1996;312:1669.
15. Cranney A, Guyatt G, Krobicki N, et al. A meta-analysis of etidronate for the treatment of post-menopausal osteoporosis. Osteoporosis Int 2001;12:140-51.
16. Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians, 2002.
17. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
18. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. J Rheumatol 1994;21:1922-6.
19. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid- induced osteoporosis. Am J Med 1995;99:235-42.
20. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:342-7.
21. Roux C, Oriente P, Laan R, et al. Randomised trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 1998;83:1128-33.
22. Pitt P, Li F, Todd P, et al. A double-blind, placebo-controlled study to determine the effects of intermitted cyclical etidronate on bone mineral density in patients on long term oral corticosteroid treatment. Thorax 1998;53:351-6.
23. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on one mineral density and vertebral fracture in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001;44:202-11.
24. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
25. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000;39:1383-9.
26. Finch S, Doyle W, Lowe C, et al. National Diet and Nutrition Survey: people 65 years and over. Volume 1: Report of the diet and nutrition survey. London: The Stationery Office, 1998.
27. Koster JC, Hackeng WHL, Mulder H. Diminished effect of etidronate in vitamin D-deficient osteopenic post-menopausal women. Eur J Clin Pharmcol 1996;51:145-7.
28. Selby PL, Halsey JP, Adams KRH, et al. Corticosteroids do not alter the threshold for vertebral fractures. J Bone Miner Res 2000;15:952-6.
29. Luengo M, Picado C, Delrio L, et al. Vertebral fractures in steroid-dependent asthma and involutional osteoporosis - a comparative study. Thorax 1991;46:803-6.
30. Johnell O, de Laet C, Johansson H, et al. Oral corticosteroids increase fracture risk independently of BMD. Osteoporosis Int 2002;13(Suppl 1):S14.
31. Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
32. Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
33. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
34. Packe GE, Douglas JG, McDonald AF, et al. Bone density in asthmatic patients taking high-dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992;47:414-7.
35. Wisniewski AF, Lewis SA, Green DJ, et al. Cross-sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997;52:853-60.
36. Israel E, Banerjee TR, Fitzmaurice GM, et al. Effects of inhaled glucocorticoids on bone density in pre-menopausal women. N Engl J Med 2001;345:941-7.
37. Wong CA, Walsh LJ, Smith CJP, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000;355:1399-403.
38. Medici TC, Grebski E, Häcki M, et al. Effects of one year treatment with inhaled fluticasone dipropionate or beclamethasone dipropionate on bone density and bone metabolism: a randomised, parallel-group study in adult asthmatic subjects. Thorax 2000;55:375-82.
39. Egan JJ, Maden C, Kalra S, et al. A randomised, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J 1999;13:1267-75.
40. Matsumoto H, Ishihara K, Hasegawa T, et al. Effects of inhaled corticosteroid and short courses of oral corticosteroids on bone mineral density in asthmatic patients: a 4-year longitudinal study. Chest 2001;120:1468-73.
41. van Staa TP, Leufkens HGM, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581-8.
42. Hubbard RB, Smith JP, Smeeth L, et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002;166:1563-6.
43. Jones A, Fog JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive airways disease. In: Cochrane Library. Issue 2. Oxford: Update Software, 2002.
44. Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8.